Suven Pharmaceuticals Ltd. (COHANCE) Stock Price & Analysis

3 Followers

COHANCE Stock Chart & Stats

₹458.55-₹13.00(-2.76%)

At close: Nov 13 3:30 PM GMT+5:30

Day’s Range: INR 456.15 - INR 475.95
52-Week Range: INR 267.85 - INR 629.45
Previous Close: INR 471.55
Volume: N/A
Average Volume (3M): 52.98K
Market Cap: INR 180.41B
Enterprise Value: INR 180.22B
Total Cash (Recent Filing): INR 2.93B
Total Debt (Recent Filing): INR 4.48B
Price to Earnings (P/E): 266.6
Beta: 0.85
Next Earnings: Feb 08, 2027 (Est.)
EPS Estimate: 0.91
Last Dividend Ex-Date: Sep 09, 2022
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Rapid FY2026 revenue growth indicates stronger customer activity and expanding commercial demand for the company’s pharmaceutical development and manufacturing services. If sustained, this larger revenue base can support scale benefits, broader customer programs, and future earnings recovery.

Conservatively Financed Balance Sheet

Very low leverage gives Suven financial flexibility to fund capacity, development programs, and working-capital needs without heavy dependence on borrowing. The larger equity and asset base also improves resilience if pharmaceutical demand or customer project timing becomes less predictable.

Improved Operating Cash Flow

Improved operating cash flow provides an important foundation for funding the business internally, even though overall cash conversion weakened. Stronger cash generation from operations can support ongoing customer programs and reduce reliance on external financing over the medium term.

Bears Say

Sharp Margin Compression

The steep decline in gross and net margins shows that higher sales are currently producing a much smaller profit contribution. Persistent margin pressure would weaken earnings quality, reduce reinvestment capacity, and make results more dependent on continued revenue growth rather than efficient execution.

Weak Free-Cash-Flow Conversion

Low conversion of accounting profit into free cash flow limits the resources available for capacity expansion, debt reduction, and shareholder returns. The deterioration from stronger conversion in FY2022–FY2024 suggests working-capital or reinvestment demands may remain a material drag on financial quality.

Severe Earnings Per Share Decline

A sharp EPS contraction indicates that the substantial revenue increase has not translated into comparable per-share earnings growth. This weakens the near-term earnings base and signals that profitability, rather than demand alone, is the key challenge for sustained shareholder value creation.

Suven Pharmaceuticals Ltd. News

Cohance Lifesciences Sets Investor Call on Q2 and H1 FY27 Results

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has issued an announcement. Cohance Lifesciences Limited has scheduled an investor and analyst conference call on November 06, 2026, at 6:30 p.m. IST to

2w ago

Cohance Lifesciences Secures Government Nod for New Chairman and Group CEO

The latest announcement is out from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ). Cohance Lifesciences Limited has received approval from the Ministry of Corporate Affairs for the appointment of Mr. Umang

1M ago

Cohance Lifesciences Boosts Employee Incentives With New ESOP Grants

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) just unveiled an update. Cohance Lifesciences Limited has approved a fresh grant of employee stock options under two existing ESOP schemes as part of

1M ago

Cohance Lifesciences Names New CFO and Tightens Disclosure Policy

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has issued an announcement. Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, operates in the lifesciences and pharmaceutical industry and is listed on both BSE

1M ago

Cohance Lifesciences Completes USFDA Inspection at Shamshabad Plant

An update from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences Limited has reported the completion of a United States Food and Drug Administration inspection at its

2M ago

Berhyanda affirms no new encumbrances on Cohance Lifesciences promoter shares for FY 2025-26

The latest update is out from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ). Berhyanda Limited, a promoter of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals), has informed Indian stock exchanges that it

4M ago

Cohance Lifesciences CFO and Whole-Time Director Himanshu Agarwal to Resign in September 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an update. Cohance Lifesciences Limited has announced that Himanshu Agarwal, its whole-time director and chief financial officer, has tendered his resignation to

5M ago

Cohance Lifesciences Says Volume Surge in Shares Is Market-Driven

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has shared an update. Cohance Lifesciences has responded to a query from the National Stock Exchange of India regarding a significant increase in trading

7M ago

Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary and Compliance Officer

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an announcement. Cohance Lifesciences has appointed Sisir K. Mishra as its Company Secretary, Compliance Officer and Key Managerial Personnel, effective April 9,

7M ago

Cohance Lifesciences Grants 198,711 Stock Options Under ESOP 2023

An announcement from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences has approved the grant of 198,711 stock options to eligible employees of the company and its

8M ago

COHANCE FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹629.45 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹180.41B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s next earnings report is estimated for Feb 08, 2027 (not yet confirmed), which is in 85 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on Nov 06, 2026. The company reported ₹0.4 earnings per share for the quarter, beating the consensus estimate of -₹0.04 by ₹0.44.

Is Suven Pharmaceuticals Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a dividend of ₹5 which represents an annual dividend yield of ―. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 0.91.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,597,320 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of ₹0.4 in its last earnings report, beating expectations of -₹0.04. Following the earnings report the stock price went down -3.591%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:COHANCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description